Fusion Pharmaceuticals, Inc.

Fusion Pharmaceuticals Inc. discovers and develops novel targeted alpha therapeutics (TAT) and radiopharmaceuticals for the diagnosis and treatment of chemotherapy resistant cancers. Fusion Pharmaceuticals serves health care sectors in Canada.
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Fusion Pharmaceuticals, Inc. balance sheet

Report period2018 2019 2020 2021 2022 Q1 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Fusion Pharmaceuticals, Inc. cash flows

Report period2018 2019 2020 2021 2022 Q1 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Fusion Pharmaceuticals, Inc. multipliers

Report period2018 2019 2020 2021 2022 Q1 23 TTM
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Fusion Pharmaceuticals, Inc. profitability

Report period2018 2019 2020 2021 2022 Q1 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Fusion Pharmaceuticals, Inc. assets
Fusion Pharmaceuticals, Inc. cash flows
Fusion Pharmaceuticals, Inc. news
10.05.2022
Fusion Pharmaceuticals' GAAP loss for 3 months of 2022 was $19.909 million, up 13.6% from $17.529 million in the previous year. Revenues were $585,000. The company did not generate revenues a year earlier.
Source: {source} pictogram ir.fusionpharma.com
Pictogram next
17.03.2022
Fusion Pharmaceuticals' GAAP loss for 2021 was $81.047 million, up 3.5% from $78.333 million in the previous year. Revenue was $1.44 million. The company did not generate revenue last year.
Source: {source} pictogram ir.fusionpharma.com
Pictogram next
09.11.2021
Fusion Pharmaceuticals' GAAP loss for 9M 2021 was $63.811 million, down 1.8% from $64.948 million in the prior year. Revenue was $846,000. The company had no revenue a year earlier.
Source: {source} pictogram ir.fusionpharma.com
Pictogram next
10.08.2021
Fusion Pharmaceuticals' GAAP loss for 6M 2021 was $44.82 million, down 18.4% from $54.955 million in the previous year. Revenue was $521,000. A year earlier, the company not generated revenue.
Source: {source} pictogram ir.fusionpharma.com
Pictogram next
All Fusion Pharmaceuticals, Inc. news
General information
Company nameFusion Pharmaceuticals, Inc.
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6 289-799-0891
Mailing address270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6
Websitewww.fusionpharma.com
Information disclosurewww.sec.gov